AIM ImmunoTech Inc.

AIM

US00901B3033

Biotechnology & Medical Research

Market Closed - NYSE Other stock markets 16:00:00 2026-06-12 EDT			5-day change	1st Jan Change
0.4059 ^USD	-11.74%		-31.35%	-64.04%

06-09	AIM ImmunoTech Launches $2.7 Million Registered Direct Offering, Private Placement	MT
06-08	Aim Immunotech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen in Combination with Astrazeneca?S Imfinzi for the Treatment of Pancreatic Cancer	CI

Top Premarket Decliners

Published on 05/20/2026 at 07:49 am EDT

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about AIM ImmunoTech Inc.

06-09	AIM ImmunoTech Launches $2.7 Million Registered Direct Offering, Private Placement	MT
06-08	Aim Immunotech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen in Combination with Astrazeneca?S Imfinzi for the Treatment of Pancreatic Cancer	CI
06-08	AIM ImmunoTech Says Pancreatic Cancer Drug Has Shown 'Positive Progress' in Phase 2 Study; Shares Rise Pre-Bell	MT
06-04	AIM ImmunoTech Inc. - Special Call
06-01	AIM ImmunoTech Inc. Completes Enrollment in Phase 2 DURIPANC Clinical Trial for Ampligen Combined with Imfinzi in Metastatic Pancreatic Cancer	CI
05-20	Top Premarket Decliners	MT
05-19	AIM ImmunoTech announces significant increase in stockholder equity and extension of promissory note maturity date to June 2027	RE
05-19	AIM ImmunoTech Inc. Amends Promissory Note Agreement With Streeterville Capital and Extends Maturity Date to June 30, 2027	CI
05-15	AIM ImmunoTech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-07	Aim ImmunoTech announces 50% objective response rate (ORR) in UPMC recurrent ovarian cancer Phase 2 clinical trial, suggesting breakthrough combination potential	RE
05-07	Aim Immunotech Inc Announces 50% Objective Response Rate in Upmc Recurrent Ovarian Cancer Phase 2 Clinical Trial	CI
04-16	AIM ImmunoTech Starts Late-Stage Trial of Ampligen in Pancreatic Cancer	MT
04-16	AIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen in Pancreatic Cancer	CI
04-13	Aim ImmunoTech provides routine update on annual filings	RE
03-27	AIM ImmunoTech Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

AIM ImmunoTech Inc. is an immuno-pharma company. The Company is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Companyâ€™s flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) and highly selective TLR3 agonist immuno-modulator, which is being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.

Employees

Sector

Biotechnology & Medical Research

More about the company